Global Gabapentin Market – Industry Trends and Forecast to 2030

Global Gabapentin Market, By Product Type (Capsule, Tablet), Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome), Route of Administration (Oral, Parenteral, Intravenous), Mode of Purchase (Prescription, Retail and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.

Gabapentin Market Analysis and Size

The increased incidence of seizures, rise in geriatric population, increase number of government initiatives, ease of purchase, investment by R&D in pharmaceutical companies and rising product approvals are predicted to drive the market growth. However, the lack of health remuneration policies, rise in cost, side effects associated and strict regulatory policies are expected to hinder the market growth. The rise of emerging markets in developing countries, rise of untapped opportunities, upcoming healthcare clinics, and enhanced bioavailability, strategic initiatives by manufacturers are the opportunities which are projected to bolster the market growth. The lack of expertise, rise in product (antibiotic) recalls, use of alternatives, issues in supply chain management in drug transportation are the challenges which can tamper the market growth.

Data Bridge Market Research analyses that the global gabapentin market which was USD 2,472.84 million in 2022, is expected to reach USD 3,021.80 million by 2030, and is expected to undergo a CAGR of 2.6% during the forecast period 2023-2030.  The “tablet” segment is expected to dominate the market due to patient’s preference. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gabapentin Market Scope and Segmentation

Market Definition

Gabapentin, in the industry of pharmaceuticals, is a drug belonging to the anticonvulsant class of medications. It was initially developed to treat epileptic seizures, specifically partial seizures. Over time, its use has expanded to include the management of neuropathic pain and certain types of chronic pain. Gabapentin functions by affecting the nerves and chemicals in the body that are involved in causing seizures and various types of pain.

Global Gabapentin Market Dynamics

Drivers

• Growing Prevalence of Neuropathic Pain Disorders

The rising incidence of neuropathic pain disorders globally is a significant driver for the global gabapentin market. Neuropathic pain, often associated with conditions like diabetic neuropathy, post-herpetic neuralgia, and trigeminal neuralgia, necessitates effective pain management. Gabapentin has proven efficacy in managing neuropathic pain, driving its demand and adoption.

• Expanding Applications and Off-Label Usage  

Gabapentin's versatility in treating various medical conditions beyond its initial intended use, such as anxiety disorders, migraines, and restless legs syndrome, contributes to market growth. Physicians and healthcare practitioners increasingly prescribe gabapentin off-label for these conditions, broadening its market reach and fueling demand.

Opportunity

• Rising Awareness and Education Initiatives

There is a substantial opportunity for market growth through increased awareness and educational initiatives regarding gabapentin's benefits, optimal usage, and potential side effects. Educating healthcare professionals, patients, and caregivers about the appropriate use of gabapentin, its efficacy in managing various conditions, and safety precautions can enhance its acceptance and adoption. This educational approach can not only expand the market but also foster responsible usage, which is crucial in ensuring positive outcomes and mitigating potential risks.

Restraint/Challenge

• Concerns Regarding Abuse and Dependency

One significant restraint for the global gabapentin market is the rising concern regarding its potential for abuse and dependency. Reports of misuse and addiction, particularly when combined with other substances like opioids, have raised regulatory scrutiny and led to tighter control and monitoring of gabapentin prescriptions. This has the potential to limit its usage and impact the overall market growth.

This global gabapentin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gabapentin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.  

Recent Development

• In September 2023, Pfizer Inc. and BioNTech SE have announced that they received approval from the U.S. Food and Drug Administration (FDA) for their supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation). This approval covers individuals aged 12 and above, and it includes emergency use authorization for children aged 6 months to 11 years, specifically for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The current vaccine season's recommendation is for a single dose for most individuals aged 5 and older. However, children under 5 years old may qualify for additional doses of this season's vaccine if they have not already completed a three-dose series with earlier formulations of a COVID-19 vaccine

 Global Gabapentin Market Scope

The global gabapentin market is segmented on the basis of product type, application, route of administration, mode of purchase and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Capsule
• Tablet

 Application

• Epilepsy
• Neuropathic Pain
• Restless Legs Syndrome

Route of Administration

• Oral
• Parenteral
• Intravenous

Mode of Purchase

• Prescription
• Retail
• Over the counter

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Gabapentin Market Regional Analysis/Insights

The global gabapentin market is analysed and market size insights and trends are provided by country, product type, application, route of administration, mode of purchase and distribution channel as referenced above.

The countries covered in the global gabapentin market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates and register the highest growth rate in the global gabapentin market due to rise in the surge in the approvals of products for the treatment and rise in the initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease in this region. Asia-Pacific is the expected region in terms of growth in global gabapentin market due to rise in the prevalence of acute lymphocytic/lymphoblastic leukaemia (ALL) in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the Market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global gabapentin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global gabapentin market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global gabapentin market. The data is available for historic period 2015-2020.

Competitive Landscape and Gabapentin Market Share Analysis

The global gabapentin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global gabapentin market.

Some of the major players operating in the global gabapentin market are:

• Amgen Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Erytech Pharma (France)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Rare Disease Therapeutics, Inc. (U.S.)
• Sanofi (France)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Genmab A/S (Denmark)
• Baxter (U.S.)
• Gilead Sciences, Inc. (U.S.)
• CELGENE CORPORATION (U.S.)
• Eisai Co., Ltd. (Japan)
• SymBio Pharmaceuticals Limited (Japan)
• Kiadis Pharma (Netherlands)
• OBI Pharma (Taiwan)
• Astellas Pharma Inc. (Japan)
• Medexus Pharma, Inc. (Canada)